Sponsor

PhaseBio Pharmaceuticals Inc.

Clinical research sponsor

Published trials13
Recruiting shown0
Roles1
SourceClinicalTrials.gov

Clinical trials

13 shown
Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS).NCT04433546 · lead sponsor · 2020-07-15
TERMINATED
Long-Term, Open Label Extension Study of Pemziviptadil (PB1046) in PAH Subjects Following Completion of Study PB1046-PT-CL-0004NCT03795428 · lead sponsor · 2019-04-10
TERMINATED
Phase 2 Study to Assess Safety, Tolerability and Efficacy of Once Weekly SC Pemziviptadil (PB1046) in Subjects With Symptomatic PAHNCT03556020 · lead sponsor · 2018-07-15
TERMINATED
A Study to Assess the Safety, Tolerability, and Hemodynamic Response of PB1046 in Subjects With PAHNCT03315507 · lead sponsor · 2017-10-20
COMPLETED
Study to Assess the Safety, Tolerability and PK/PD After 4 Weekly SC Injections of PB1046 in Subjects With Stable HFrEFNCT02808585 · lead sponsor · 2016-06-01
COMPLETED
Study to Assess the Safety, Tolerability, PK and PD Response of PE0139 Injection in Adult Subjects With T2DMNCT02581657 · lead sponsor · 2015-10-01
COMPLETED
Phase 1, Randomized, Double-Blind, Placebo-Controlled Exploratory Study That Will Assess the Safety, Tolerability, Pharmacokinetics and Hemodynamic Response to a Single 30 Minute Intravenous Infusion of Vasomera™ (PB1046) in Adult Subjects With Stage 1 or 2 Essential HypertensionNCT01873885 · lead sponsor · 2013-06-01
COMPLETED
Phase 1 Multicenter, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Response of PE0139 Injection in Adult Subjects With Type 2 Diabetes MellitusNCT01835730 · lead sponsor · 2013-04-01
COMPLETED
Phase 2b Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Assess the PD Response and Safety of Three Dose Levels of (PB1023) Injection Following 20 Weeks of Weekly SC Dosing in Adults With T2DMNCT01658501 · lead sponsor · 2012-07-01
COMPLETED
Pharmacokinetic Profile of Two Formulations of PB1023 Following Single Subcutaneous Injection in Subjects With Type 2 Diabetes MellitusNCT01427257 · lead sponsor · 2012-02-01
COMPLETED
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Response of Vasomera (PB1046) Injection Following a Single Subcutaneous Dose in Subjects With Stage 1 or 2 Essential HypertensionNCT01523067 · lead sponsor · 2012-01-01
COMPLETED
Pharmacokinetic, Safety/Tolerability Study of a Single SC Dose of PB1023 Injection in Subjects With Normal and Impaired Renal FunctionNCT01478399 · lead sponsor · 2011-12-01
COMPLETED
Phase 1/2a, Randomized, Double-Blind, Placebo-Controlled, Study to Assess Safety, Tolerability, PK and PD Response of PB1023 Injection Following Single and Multiple SQ Doses in Adults With Type 2 Diabetes MellitusNCT01236404 · lead sponsor · 2010-11-01
COMPLETED

Sponsor roles

lead sponsor13

How to interpret this record

CureCurrent links normalized diseases, medicines, registry study labels, sponsors and research sites. A link is not the same as a finding of clinical effectiveness. Our research guides explain how to compare studies, decode RxNorm identities, and avoid over-interpreting site and trial counts. See the published database coverage for mapping completeness.

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.